Success Metrics

Clinical Success Rate
85.0%

Based on 68 completed trials

Completion Rate
85%(68/80)
Active Trials
10(8%)
Results Posted
50%(34 trials)
Terminated
12(10%)

Phase Distribution

Ph not_applicable
24
20%
Ph phase_1
27
23%
Ph phase_3
20
17%
Ph phase_2
12
10%
Ph phase_4
28
24%
Ph early_phase_1
4
3%

Phase Distribution

31

Early Stage

12

Mid Stage

48

Late Stage

Phase Distribution115 total trials
Early Phase 1First-in-human
4(3.5%)
Phase 1Safety & dosage
27(23.5%)
Phase 2Efficacy & side effects
12(10.4%)
Phase 3Large-scale testing
20(17.4%)
Phase 4Post-market surveillance
28(24.3%)
N/ANon-phased studies
24(20.9%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

73.9%

68 of 92 finished

Non-Completion Rate

26.1%

24 ended early

Currently Active

10

trials recruiting

Total Trials

118

all time

Status Distribution
Active(12)
Completed(68)
Terminated(24)
Other(14)

Detailed Status

Completed68
unknown13
Terminated12
Withdrawn12
Recruiting7
Active, not recruiting3

Development Timeline

Analytics

Development Status

Total Trials
118
Active
10
Success Rate
85.0%
Most Advanced
Phase 4

Trials by Phase

Early Phase 14 (3.5%)
Phase 127 (23.5%)
Phase 212 (10.4%)
Phase 320 (17.4%)
Phase 428 (24.3%)
N/A24 (20.9%)

Trials by Status

recruiting76%
terminated1210%
withdrawn1210%
active_not_recruiting33%
unknown1311%
enrolling_by_invitation11%
not_yet_recruiting11%
completed6858%
suspended11%

Recent Activity

Clinical Trials (118)

Showing 20 of 118 trialsScroll for more
NCT05470283Phase 1

Phase I, Open-Label, Study of Tumor Infiltrating Lymphocytes Engineered With Membrane Bound IL15 Plus Acetazolamide in Adult Patients With Metastatic Melanoma

Active Not Recruiting
NCT06899061Phase 1

Modular Clinical Pharmacology Study to Evaluate the Drug-drug Interaction Potential and Relative Bioavailability of Saruparib

Active Not Recruiting
NCT07431866Phase 1

A Clinical Study of the Effect of MK-2828 on Rosuvastatin or Furosemide in Healthy People (MK-2828-005)

Recruiting
NCT03511118

Pharmacokinetics and Safety of Commonly Used Drugs in Lactating Women and Breastfed Infants

Recruiting
NCT03892148Phase 4

Protocol of Diuretics Use in Congestive Therapy in Heart Failure

Completed
NCT07348510Not Applicable

Diuretic Effect of Aminophylline and Furosemide in Adult Patients Undergoing Cardiac Surgical Procedures

Recruiting
NCT06036914Phase 2

A Study of Ultra High Dose Diuretics to Treat Heart Failure

Completed
NCT07336485Not Applicable

Forced Diuresis After Flexible Ureteroscopy for Medium-Sized Renal Stones

Completed
NCT05741372Not Applicable

A Study to Compare How Different Medicines (Rosuvastatin, Digoxin, Metformin, and Furosemide) Are Handled by the Body of Healthy People and People With Liver Cirrhosis

Completed
NCT06765031Not Applicable

The Role of Furosemide Stress Test in the Intensive Care Clinic

Recruiting
NCT06504862Phase 1

A Study in Healthy Men to Test Whether Zongertinib Influences the Amount of 4 Other Medicines (Dabigatran, Rosuvastatin, Metformin, and Furosemide) in the Blood

Completed
NCT04481789Phase 1

Clinical Pharmacology Study of Oral Edaravone in Healthy Adult Males (Drug Interaction Study and Preliminary Regimen-Finding Study)

Completed
NCT06941415Phase 3

Bumetanide vs. Furosemide in Cirrhosis

Not Yet Recruiting
NCT05779943Phase 2

Comparison of 18F-rhPSMA-7.3 PET/CT With and Without Furosemide in Biochemical Recurrence of Prostate Cancer

Active Not Recruiting
NCT03296813Phase 3

TRANSFORM-HF: ToRsemide compArisoN With furoSemide FORManagement of Heart Failure

Completed
NCT07173738Phase 1

Pharmacokinetics, Safety and Tolerability of Concurrent Doses of BIA 5-1058 and Furosemide

Completed
NCT05915286Phase 4

Diuretic Use in Hemodialysis Patients With Residual Renal Function

Suspended
NCT05986773Phase 4

Diuretic Strategies in Acute Heart Failure Patients at High Risk for Diuretic Resistance

Terminated
NCT06821594Early Phase 1

Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts at Tertiary Care Hospital in Karachi.

Enrolling By Invitation
NCT04180397Phase 4

Controlled Fluid Removal in Critical Ill Patients With Fluid Overload in the Intensive Care Unit.

Recruiting

Drug Details

Intervention Type
DRUG
Total Trials
118